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A B S T R A C T
Arboviral diseases caused by dengue (DENV), Zika (ZIKV) and chikungunya (CHIKV) viruses represent a major
public health problem worldwide, especially in tropical areas where millions of infections occur every year. The
aim of this research was to identify candidate molecules for the treatment of these diseases among the drugs
currently available in the market, through in silico screening and subsequent in vitro evaluation with cell culture
models of DENV and ZIKV infections. Numerous pharmaceutical compounds from antibiotics to chemother-
apeutic agents presented high in silico binding affinity for the viral proteins, including ergotamine, antrafenine,
natamycin, pranlukast, nilotinib, itraconazole, conivaptan and novobiocin. These five last compounds were
tested in vitro, being pranlukast the one that exhibited the best antiviral activity. Further in vitro assays for this
compound showed a significant inhibitory effect on DENV and ZIKV infection of human monocytic cells and
human hepatocytes (Huh-7 cells) with potential abrogation of virus entry. Finally, intrinsic fluorescence analyses
suggest that pranlukast may have some level of interaction with three viral proteins of DENV: envelope, capsid,
and NS1. Due to its promising results, suitable accessibility in the market and reduced restrictions compared to
other pharmaceuticals; the anti-asthmatic pranlukast is proposed as a drug candidate against DENV, ZIKV, and
CHIKV, supporting further in vitro and in vivo assessment of the potential of this and other lead compounds that
exhibited good affinity scores in silico as therapeutic agents or scaffolds for the development of new drugs against
arboviral diseases.
1. Introduction
The incidence of dengue, Zika and chikungunya viral infections has
grown dramatically around the world, becoming a global public health
concern, with cases reported in more than 100, 80 and 40 countries,
respectively (Calvo et al., 2015; Gardner et al., 2018; Mayer et al.,
2017; Villegas et al., 2018; Walker et al., 2014; World Health
Organization, 2018, 2017, 2016). Several vaccine candidates have been
evaluated in preclinical and clinical trials (Hallengärd et al., 2014;
López-Camacho et al., 2018; Roy et al., 2014; Smalley et al., 2016).
However, there are no licensed vaccines against Zika and chikungunya
and there exists uniquely one registered vaccine against dengue, called
Dengvaxia, which only confer partial immunity and has some safety
warnings (Aguiar and Stollenwerk, 2018; Flasche et al., 2016; Guzman
et al., 2013; Halstead, 2017; Scherwitzl et al., 2017; Whitehead and
Subbarao, 2017). The absence of approved antiviral drugs to combat
these diseases (Low et al., 2017; Tomlinson et al., 2009) and the in-
crease in the endemic zone of the vectors due to the climate change and
unplanned urbanization (Ebi and Nealon, 2016; Liu-Helmersson et al.,
2016), evidence the need for the development of potent anti-dengue
drugs.
Flaviviruses such as dengue (DENV) and Zika (ZIKV) (belonging to
the Flaviviridae family), and alphaviruses such as chikungunya (CHIKV)
(belonging to the Togaviridae family) are small, enveloped, single-
stranded, positive-sense RNA viruses, transmitted primarily by Aedes
spp. mosquitoes (Lazear et al., 2016; Weaver, 2014). As part of their
viral replication cycle, DENV, ZIKV and CHIKV enter host cells via viral
glycoprotein receptor-mediated endocytosis to use the machinery of the
https://doi.org/10.1016/j.antiviral.2019.104668
Received 22 November 2019; Accepted 27 November 2019
∗ Corresponding author.
E-mail address: dmontesg@unicartagena.edu.co (D. Montes-Grajales).
1 These authors contributed equally.
Antiviral Research 173 (2020) 104668
Available online 28 November 2019
0166-3542/ © 2019 Elsevier B.V. All rights reserved.
T
infected cell to synthesize viral proteins and replicate their genome (Dai
et al., 2016; Harrison, 2015; Marsh and Pelchen-Matthews, 1993; Más
and Melero, 2013). The viral RNA genome encodes a single polyprotein
containing three structural proteins incorporated into the virions
(capsid (C), pre-membrane/membrane (prM/M) and envelope (E)), and
seven non-structural proteins (NS1, NS2A, NS2B, NS3, NS4A, NS4B and
NS5) that coordinates virus replication, assembly and modulation of
host defense mechanisms. The molecular mechanism responsible for the
development of disease (Eglen et al., 2000) is mediated by viral pro-
teins, which constitute target molecules in drug development
(Bekerman and Einav, 2015; Klumpp and Crépin, 2014; Liang et al.,
2016). Therefore, the purpose of this research was to identify in silico
candidate molecules among known pharmaceuticals with the potential
to bind DENV, ZIKV and CHIKV proteins to help to prioritize com-
pounds for in vitro an in vivo evaluation; with further in vitro antiviral
activity assessment of five selected compounds. This drug repurposing
(or repositioning) strategy was used to accelerate the discovery of safe
and efficient treatments for patients (Abdulla et al., 2009; Bastos and
Coelho, 2014; Langedijk, 2016; Ma et al., 2013; Mehndiratta et al.,
2016; O'Connor and Roth, 2005; Pushpakom et al., 2018; J. Zhang
et al., 2017).
2. Methods
2.1. Viral proteins and ligands structures
The crystallographic coordinates of DENV, ZIKV and CHIKV pro-
teins, with suitable resolution for docking studies (on average ≤ 2.0 Å),
were downloaded from Protein Data Bank (PDB) (http://www.rcsb.
org/) in pdb format, and prepared as described in our previous article
(Montes-Grajales et al., 2016).
Small-molecule drug structures were obtained from the database of
approved pharmaceuticals on DrugBank (http://www.drugbank.ca) as
sdf files and converted to mol2 format using Open Babel (O'Boyle et al.,
2011). The molecular structures were prepared using AutoDockTools
1.5.6 (Morris et al., 2009) by adding Kollman charges and polar hy-
drogen atoms and were saved in pdbqt files.
2.2. Virtual screening protocol
The virtual screening protocol was the same used by Cabarcas-
Montalvo et al. (2016), which has been validated with experimental
assays for DENV proteins, as well as for other datasets in our previous
studies (Cabarcas-Montalvo et al., 2016; Montes-Grajales et al., 2016,
2013; Montes-Grajales and Olivero-Verbel, 2013). Blind docking tech-
nique was employed with the purpose of finding promising lead com-
pounds in existing drugs to target DENV, ZIKV and CHIKV proteins
according to their AutoDock Vina affinity score (kcal/mol) (Trott and
Olson, 2010). The settings used were: number of modes of 20, an energy
range of 1.5, and exhaustiveness equal to 20. Simulations were per-
formed in triplicate, keeping the best pose for each run. Finally, average
affinities for the best poses were taken as the final value.
Additionally, a heatmap was created using R (R Core Team, 2016)
with the affinity scores between pharmaceuticals and viral proteins, by
using the “heatmap.2” function included in the gplot library (Warnes
et al., 2009). The range color was defined implementing RColorBrewer,
assigning red from −12.0 kcal/mol to −7.0 kcal/mol (strong and
moderate), white from −7.0 kcal/mol to −6.0 kcal/mol (weak), and
blue to affinities greater than −6.0 kcal/mol.
2.3. Evaluation of protein−ligand interactions
The best pose of the small-molecule drugs with the best affinity
scores for the tested viral proteins were isolated in AutoDock Tools
1.5.6 (Morris et al., 2009) from the AutoDock Vina docking resultant
files and merged with the optimized protein structures in pdb format
using Pymol (Seeliger and de Groot, 2010). Contact residues of these
merged structures were analyzed with LigandScout 3.0 (Wolber and
Langer, 2005), setting the interaction cutoff threshold to 7 Å (Montes-
Grajales and Olivero-Verbel, 2013).
2.4. Assessment of antiviral activity in DENV and ZIKV infection in vitro
To assess the potential inhibitory effect of pranlukast, nilotinib,
conivaptan, itraconazole, and novobiocin (Suppl. Table 1) on the in-
fectivity of enveloped viruses, we performed experimental infections in
vitro using a human monocytic cell line expressing the attachment





CHIKV nsP2 Non-structural polyprotein 2
DENV dengue virus
DENV-2 dengue virus type 2
DENV-3 dengue virus type 3
DENV C Capsid
DENV NS2B/NS3 Non-structural protein 2B/non-structural protein
3 complex
DENV NS5 DENV non-structural protein 5
DENV2 E DENV-2 virus envelope glycoprotein




nsP2 nonstructural polyprotein 2
PDB Protein Data Bank
ZIKV Zika virus
ZIKV C Capsid protein from Zika Virus
ZIKV E Domain III of envelope protein
ZIKV MTase ZIKV MTase
ZIKV NS1 Zika virus non-structural protein 1
ZIKV NS2B/NS3 NS2B-NS3 protease
ZIKV NS3NS3 protease
ZIKV NS5NS5 RNA-dependent RNA polymerase (RdRP)
Table 1
List of studied proteins.
Name Abbreviation PDB ID Organism
DENV-2 virus envelope glycoprotein DENV2 E 1OK8 DENV
DENV Capsid DENV C 1R6R DENV
DENV non-structural protein 2B/non-
structural protein 3 complex
DENV NS2B/NS3 2FOM DENV
DENV non-structural protein 5 DENV NS5 2J7U DENV
DENV-3 non-structural protein 5 DENV3 NS5 5JJS DENV
ZIKV Domain III of envelope protein ZIKV E 5OMZ ZIKV
ZIKV Capsid Protein from Zika Virus ZIKV C 5YGH ZIKV
ZIKV NS5 MTase ZIKV MTase 5WXB ZIKV
Zika virus non-structural protein 1 ZIKV NS1 5K6K ZIKV
ZIKV NS2B-NS3 protease ZIKV NS2B/NS3 5H4I ZIKV
ZIKV NS3 protease ZIKV NS3 5YOD ZIKV
ZIKV NS5 RNA-dependent RNA
polymerase (RdRP)
ZIKV NS5 5WZ3 ZIKV
CHIKV envelope 1 CHIKV E1 3N40 CHIKV
CHIKV envelope 2 CHIKV E2 3N44 CHIKV
CHIKV non-structural polyprotein 2 CHIKV nsP2 3TRK CHIKV
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and ZIKV infection (Kraus et al., 2007; Montoya et al., 2018). All drugs
were tested under conditions and concentrations that did not affect cell
viability (Suppl. Fig. 1). A detailed description is provided in Suppl.
Methods.
2.5. Fluorescence microscopy
The antiviral effect of pranlukast was additionally examined using
the human hepatocyte cell line (Huh-7), widely described to be highly
susceptible to DENV and ZIKV infection in vitro (Chan et al., 2016; Soto-
Acosta et al., 2013). Additional characterization of the imaging method
and infected cell count is given in Suppl. Methods.
2.6. Intrinsic fluorescence assay
To evaluate the potential interactions between pranlukast and ni-
lotinib with some of the viral proteins identified after in silico analyses,
we measured the intrinsic fluorescence intensity values (Byrd et al.,
2013) of three recombinant proteins of DENV: envelope (recE), capsid
(C), and the non-structural protein-1 (NS1). All three recombinant
proteins used in this study: NS1 (The Native Antigen Company, Ox-
ford), C (Sino Biological, Cat# 40262-V07E) and recE (in-house pro-
duced) were certified to be>95% pure by manufacturers and in-house
Table 2
Small-molecule drugs with the best docking affinity scores (kcal/mol) for the
studied DENV, ZIKV and CHIKV proteins.
Name CID Description Docking affinity
(kcal/mol)
DENV2 E








Gliquidone 91610 Hypoglycemic −9.1 ± 0.2
DENV C
Pranlukast 4887 Antiasthmatic −9.1 ± 0.1







Nilotinib 644241 Antineoplastic −8.8 ± 0.0
Zafirlukast 5717 Antiasthmatic −8.8 ± 0.1
Nandrolone
phenpropionate
229455 Anabolic −8.8 ± 0.2
DENV NS2B/NS3 complex
Nilotinib 644241 Antineoplastic −10.6 ± 0.2
Imatinib 5291 Antineoplastic −10.2 ± 0.1
Regorafenib 11167602 Antineoplastic −10.1 ± 0.2
Ponatinib 24826799 Antineoplastic −10.1 ± 0.2|
Eltrombopag 66583167 Antithrombocytopenic −9.5 ± 0.0|
Sorafenib 216239 Antineoplastic −9.5 ± 0.0
DENV NS5
Conivaptan 151171 Vasopressin antagonist −10.6 ± 0.0
Dutasteride 6918296 Prostatic hypertrophy
agent
−10.3 ± 0.0|
Natamycin 5284447 Antifungal −9.9 ± 0.0
Tubocurarine 6000 Neuromuscular blocker −9.9 ± 0.0
Ergotamine 8223 Vasoconstrictor −9.7 ± 0.2
DENV3 NS5
Conivaptan 151171 Vasopressin antagonist −11.4 ± 0.0




Diosmin 5281613 Vasoconstrictor −11.0 ± 0.0
Irinotecan 60838 Antineoplastic −11.0 ± 0.2
ZIKV E




Nilotinib 644241 Antineoplastic −9.1 ± 0.1
Lomitapide 9853053 Antilipemic −9.0 ± 0.1
Eltrombopag 66583167 Antithrombocytopenic −8.9 ± 0.3
Conivaptan 151171 Vasopressin antagonist −8.9 ± 0.1
Gliquidone 91610 Hypoglycemic −8.9 ± 0.3
ZIKV C




Conivaptan 151171 Vasopressin antagonist −8.2 ± 0.0
Setiptiline 5205 Antidepressant −8.2 ± 0.0
Ergotamine 8223 Vasoconstrictor −8.2 ± 0.4
ZIKV MTase
Nilotinib 644241 Antineoplastic −10.8 ± 0.6
Tolvaptan 443894 Vasopressin antagonist −10.7 ± 0.0
Daunorubicin 30323 Antineoplastic −10.7 ± 0.0
Doxorubicin 31703 Antibiotic −10.7 ± 0.0
Viomycin 3037981 Antibiotic −10.5 ± 0.2
ZIKV NS1
Nilotinib 644241 Antineoplastic −9.7 ± 0.4
Eltrombopag 66583167 Antithrombocytopenic −9.6 ± 0.2
Telmisartan 65999 Antihypertensive −9.4 ± 0.4





Teniposide 452548 Antineoplastic −9.8 ± 0.1
Eltrombopag 66583167 Antithrombocytopenic −9.4 ± 0.3
Table 2 (continued)
Name CID Description Docking affinity
(kcal/mol)
Nilotinib 644241 Antineoplastic −9.4 ± 0.3
Etoposide 36462 Antineoplastic −9.2 ± 0.1









Zafirlukast 5717 Antiasthmatic −9.8 ± 0.3
Conivaptan 151171 Vasopressin antagonist −9.8 ± 0.0
Nilotinib 644241 Antineoplastic −9.6 ± 0.2
Ergotamine 8223 Vasoconstrictor −9.6 ± 0.2
ZIKV NS5




Dutasteride 6918296 5α-reductase inhibitor −10.0 ± 0.4
Nilotinib 644241 Antineoplastic −10.0 ± 0.1
Ergoloid mesylate 87068835 Vasodilator −9.9 ± 0.1
Conivaptan 151171 Vasopressin antagonist −9.9 ± 0.1
CHIKV E1
Natamycin 5284447 Antifungal −10.7 ± 0.0|
Tubocurarine 6000 Neuromuscular blocker −10.6 ± 0.0|
Eplerenone 443872 Diuretic −10.6 ± 0.0|
Nilotinib 644241 Antineoplastic −10.6 ± 0.1|





Nilotinib 644241 Antineoplastic −10.9 ± 0.1
Conivaptan 151171 Vasopressin antagonist −10.8 ± 0.2
Tubocurarine 6000 Neuromuscular blocker −10.6 ± 0.5
Ergotamine 8223 Vasoconstrictor −10.6 ± 0.0
Etoposide 36462 Antineoplastic −10.6 ± 0.0
Eltrombopag 66583167 Antithrombocytopenic −10.6 ± 0.1
Tigecycline 54686904 Antibiotic −10.6 ± 0.1
CHIKV nsP2
Irinotecan 60838 Antineoplastic −9.6 ± 0.1
Nilotinib 644241 Antineoplastic −9.6 ± 0.1
Conivaptan 151171 Vasopressin antagonist −9.5 ± 0.1
Dihydroergotamine 10531 Antimigraine −9.4 ± 0.0
Zafirlukast 5717 Antiasthmatic −9.3 ± 0.2
Telmisartan 65999 Antihypertensive −9.3 ± 0.1
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approaches as previously described (Beatty et al., 2015; Puerta-Guardo
et al., 2019a) In addition, the presence and specificity of the re-
combinant protein was demonstrated by Western blot using specific α-
NS1 (pan-flavivirus 2B7 mAb), α-capsid, α-envelope (pan-flavivirus
4G2 mAb) (Suppl. Fig. 2). Further information is presented in Suppl.
Methods.
2.7. Statistical analyses
All statistical analyses and graphs were performed and generated
using GraphPad Prism 6 software. Multiple comparison analyses be-
tween three or more groups were conducted using an ordinary two-way
analysis of variance (ANOVA). Comparison between two groups were
carried out using t tests (non-parametric) (Mann-Whitney test).
Differences were considered significant for p values < 0.05.
3. Results
3.1. Viral proteins and ligand structures
Fifteen DENV, ZIKV and CHIKV proteins (Table 1) were found to
have an available crystal structure with suitable resolution and were
Fig. 1. Three-dimensional view of the overall structures (left) and pre-
dicted binding sites (right) of the protein-ligand complexes. A. DENV2 E-
Ergotamine, B. DENV C-Pranlukast, C. DENV NS2B/NS3 protease-Nilotinib, D.
DENV NS5-Conivaptan and E. DENV3 NS5-Conivaptan complexes. Red arrows
represent hydrogen-bond acceptor features and blue arrows indicate aromatic
ring interactions.
Fig. 2. Three-dimensional view of the overall structures (left) and pre-
dicted binding sites (right) of the protein-ligand complexes. A. ZIKV E-
Ergotamine, B. ZIKV C-Dihydroergotamine, C. ZIKV NS5 MTase-Nilotinib, D.
ZIKV NS1-Nilotinib, E. ZIKV NS2B/NS3-Teniposide, F. ZIKV NS3-
Dihydroergotamine, G. ZIKV NS5-Dihydroergotamine (orange) and ZIKV NS5-
Ergotamine (green). Red arrows represent hydrogen-bond acceptor features,
blue arrows indicate aromatic ring interactions and green arrows represent
hydrogen-bond acceptor and donor features.
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downloaded from PDB (http://www.rcsb.org/) (Bernstein et al., 1977).
A total of 1,597 pharmaceutical compounds (Suppl. Table 2-4) were
obtained from DrugBank (Law et al., 2014) and prepared according to
our protocol (Cabarcas-Montalvo et al., 2016; Montes-Grajales et al.,
2016, 2013; Montes-Grajales and Olivero-Verbel, 2013).
3.2. Small molecule drugs have differential affinity to viral proteins of
DENV, ZIKV and CHIKV
AutoDock Vina affinity scores for small-molecule drugs with DENV,
ZIKV and CHIKV proteins are presented in Suppl. Tables 2-4, respec-
tively; and a summary with the best docking results per protein target
are shown in Table 2. These ranged from −11.4 to −1.0 kcal/mol.
Interestingly, several different types of drugs, including vasoconstric-
tors, analgesics, antineoplasics, anti-inflammatories, antibiotics and
antihistamines, among others, presented high affinity scores
(≤−9.0 kcal/mol) for the viral proteins tested. To better visualize
these results, a clustered heatmap based on docking affinity scores of
DENV, ZIKV and CHIKV proteins against pharmaceuticals is shown in
Suppl. Fig. 3.
Regarding DENV, the proteins DENV2 E, DENV C and DENV NS2B/
NS3 exhibited their highest docking affinity scores with the vasocon-
strictor ergotamine (−9.8 kcal/mol), the antiasmathic pranlukast
(−9.1 kcal/mol) and the antineoplastic agent nilotinib (−10.6 kcal/
mol), respectively. In addition, two DENV proteins displayed the
highest affinity with the vasopressin antagonist conivaptan, with affi-
nity scores of −10.6 kcal/mol for DENV NS5 and -11.4 kcal/mol for
DENV3 NS5. Three proteins studied from CHIKV demonstrated highest
binding affinity value: E1 with the antifungal natamycin (−10.7 kcal/
mol), and E2 and nsP2 with nilotinib (−10.9 kcal/mol and −9.6 kcal/
mol, respectively). ZIKV proteins NS1 and NS5 MTase obtained the best
affinity score with nilotinib (−9.7 and −10.8 kcal/mol, respectively);
NS5, C, and NS3 with dihydroergotamine (−10.4, −8.9 and
−10.2 kcal/mol, respectively); E and NS5 with ergotamine (−9.3 kcal/
mol and −10.4 kcal/mol, respectively), and the NS2/NS3 complex with
teniposide (−9.8 kcal/mol).
3.3. Small molecules drugs interact with distinct viral proteins via
hydrophobic interactions
Results obtained from LigandScout (Wolber and Langer, 2005)
showed that most of the protein-ligand interactions between DENV,
ZIKV and CHIKV proteins with the candidate pharmaceuticals are hy-
drophobic, with the presence of some aromatic interactions and hy-
drogen bonds. The contact residues and type of interactions of the
complexes with the best affinity scores are presented in Figs. 1–3, and
those for pranlukast are available in Suppl. Fig. 4.
3.4. Pranlukast reduces DENV and ZIKV infection of human monocytic
cells and human hepatocytes in vitro, potentially blocking virus entry
Here, human monocytic cells (U937-DC-SIGN) were infected using a
pre-mixed preparation of purified DENV or ZIKV with several con-
centrations of pranlukast, nilotinib, conivaptan, itraconazole and no-
vobiocin (Suppl. Table 1; Fig. 4). Twenty-four hours post-infection,
pranlukast was the only tested compound that significantly inhibited
the infection of U937-DC-SIGN cells, as measured by flow cytometry
using NS3 as a marker for viral replication (Fig. 4A). Compared to
DMSO-treated cells that were infected with DENV (21%) or ZIKV
(17%), pranlukast showed an important reduction in expression of NS3
in cells infected with either DENV (IC50 = 11.85 μM) or ZIKV
(IC50 = 22.28 μM) (Fig. 4A). Other compounds such as conivaptan and
novobiocin (Fig. 4C, E) showed promising inhibitory effects for both
DENV and ZIKV infections (Fig. 4C, E). In contrast, nilotinib and itra-
conazole showed no antiviral activity against either DENV or ZIKV in-
fection of human monocytic cells (Fig. 4B, D). With these results, we
additionally characterized the antiviral activity of pranlukast in DENV
and ZIKV infection in vitro by determining the percentage of infected
human monocytic cells and also the amount of virus production using
the standard Vero focus forming assay (FFU/mL). Pranlukast reduced
both the amount of DENV and ZIKV-infected cells after 24 h post-
treatment and also reduced the infectivity of virus production from
treated cells (Fig. 5A–C). A similar inhibitory effect was achieved by
different concentrations of pranlukast (range: 50–12.5 μM) in human
monocytic cells infected with DENV and ZIKV using different MOIs
(0.1, 0.5, 1)(Fig. 5D) or human hepatocytes in which pranlukast
(50–12.5 μM) but not nilotinib (25–12.5 μM) inhibited DENV and ZIKV
infection after 24 h post-treatment (Fig. 6A–C). The differences in the
concentrations tested for both compounds resulted from the analysis of
the cell viability test (Suppl. Fig. 1), which revealed that nilotinib re-
duced the viability of human monocytic cells (> 20% cytotoxicity) at
concentrations between 100 and 50 μM, while, pranlukast only affected
cell viability at 100 μM. Further, pranlukast appeared to affect the early
stages of DENV and ZIKV infection, as the percentage of infected cells
was markedly reduced when virus and pranlukast were simultaneously
added to infect U937 cells (Fig. 7A), compared to an alternative pro-
tocol when pranlukast was added 2 h after infection was initiated
(Fig. 7B). Additionally, pranlukast (50–12.5 μM) but not nilotinib
blocked more than 90% of DENV attachment to the surface of human
monocytic cells (Fig. 7C). Attached virus was removed after treatment
with glycine acid, a buffer that dissociate cell-surface associated virus
on cell membranes (Fig. 7C). Together, these data show that pranlukast
inhibited the infection of human monocytic cells with DENV or ZIKV
under the conditions tested and affected DENV absorption on cell
membranes.
Fig. 3. Three-dimensional view of the overall structures (left) and pre-
dicted binding sites (right) of the protein-ligand complexes. A. CHIKV E1-
Natamycin, B. CHIKV E2-Nilotinib, C. CHIKV nsP2-Irinotecan (magenta) and
CHIKV nsP2-Nilotinib (green) complexes. Red and green arrows represent hy-
drogen-bond acceptor and donor features, respectively.
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3.5. Pranlukast interacts with DENV proteins in vitro
Here, the intrinsic fluorescence values of three viral proteins E, C,
and NS1 (200 ng/mL) were measured in the presence and absence of
pranlukast (50 μM) and nilotinib (25 μM) (Fig. 8). All three re-
combinant proteins diluted in PBS(1x) and DMSO (0.5%) showed si-
milar fluorescence values at the wavelengths included in the assay
(300, 320, 340, 360 nm) (Fig. 8A–F). Interestingly, pranlukast sig-
nificantly decreased the intrinsic fluorescence intensities of all three
proteins, especially at the wavelength of 300 nm, where all three pro-
teins showed a peak of maximum fluorescence, which were not satur-
ating for the detection system (NS1: 25%; E: 30%; C: 20%; Fig. 8).
Neither DMSO nor nilotinib affected the intrinsic protein fluorescence
of any of these three proteins (< 1%)(Fig. 8A–F). Fluorescence values
obtained with pranlukast and nilotinib alone are presented in Figure
Suppl. Fig. 5. Together these results suggest that pranlukast interacts
with these three viral proteins in vitro.
4. Discussion
Several already-approved drugs exhibited high in silico binding af-
finity for DENV, ZIKV and CHIKV proteins; including vasoconstrictors,
analgesics, antineoplasics, anti-inflammatories, antibiotics and anti-
histamines. Interactions were predominantly hydrophobic with some
hydrogen bonds, aromatic ring interactions and negative ionizable
areas, which may contribute to stabilize the ligands at the target site
and confer high affinity (Makhatadze and Privalov, 1995; Patil et al.,
2010; Young et al., 2007).
Envelope proteins of DENV, ZIKV and CHIKV, involved in virus
binding and membrane fusion, were found to have the best in silico
affinity to many of the pharmaceutical compounds. Similar results were
found for several non-structural proteins including NS2B, NS3, and NS5
from DENV and ZIKV; as well as for ZIKV NS1 and CHIKV nsP2.
Among the compounds tested in vitro, only the anti-asthmatic drug
pranlukast exhibited a significant inhibition in the infection of human
monocytic cells and human hepatocytes with DENV and ZIKV using in
vitro cell culture models, potentially interfering with virus binding and/
or entry into target cells via direct interaction with some viral proteins
such as NS1, envelope and capsid. As a leukotriene receptor antagonist,
pranlukast has been widely used to prevent seasonal virus-induced
asthma exacerbation (Keam et al., 2003; Kim et al., 2016). However,
the potential antiviral activity of pranlukast had not been addressed.
These findings suggest that approved drugs available on the market
may have potential therapeutic application against replication/trans-
mission of arboviruses.
The in silico screening showed that pranlukast may interact with
several viral targets (Suppl. Fig. 4). The interactions among those
complexes appear to be characterized by hydrophobic interactions with
Fig. 4. Antiviral activity of in silico re-
purposed drug compounds against DENV
and ZIKV infection of human monocytic
cells in vitro. Human monocytic cells in-
fected with DENV or ZIKV in the presence
and absence of several concentrations (nM)
of pranlukast, nilotinib, conivaptan, itraco-
nazole and novobiocin (Table 1). Infection
was determined after 24 h post-infection by
detecting the viral replication marker NS3
using flow cytometry. Graphs represent the
inhibitory effect for each compound against
DENV and ZIKV infection of human mono-
cytic cells. The inhibitory effect was ex-
pressed as the relative infection of non-in-
fected cells (background) vs cells infected in
the presence or absence of eight-different
concentrations of each compound (nM).
Analyses by nonlinear regression (curve fit)
with variable slope predicted the IC50 as the
measure of the antiviral effect potency of
each compound against DENV or ZIKV in-
fection of human monocytic cells. Each
point represents the mean neutralization
value from the two replicates, and the error
bars depict the standard deviations. Neu-
tralization experiments were repeated sev-
eral times for pranlukast (n = 7), nilotinib
(n = 13), conivaptan (n = 9), itraconazole
(n = 4), and novobiocin (n = 4).
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some hydrogen bonds and aromatic-aromatic ring interactions. Pran-
lukast exhibited three polar interactions with CHIKV E1 and CHIKV E2
(ARG247F, TYR180F and LYS181F), in the same binding pocket re-
ported for other promising molecules able to inhibit CHIKV replication
(Mishra et al., 2016), and two polar interactions with DENV2 E
(SER29A and SER363A) and ZIKV E (LYS100A and PHE18A). Analyses
by intrinsic fluorescence assay, showed an apparent interaction be-
tween pranlukast and three viral proteins such as E, NS1 and C, sug-
gesting a potential antiviral mechanism of pranlukast against DENV and
ZIKV.
Here, our in vitro data showed that pranlukast possesses inhibitory
activity against DENV and ZIKV infection of human monocytic cells and
also human hepatocytes cells, two main cellular targets described for
DENV and ZIKV (Chan et al., 2016; Soto-Acosta et al., 2013). Additional
results suggested that pranlukast inhibited DENV and ZIKV infection of
human monocytic cells at different MOIs. This inhibitory effect was
mediated by blocking virus attachment, which may abrogate virus
entry. Interestingly, pranlukast interacts with DENV proteins that play
critical roles not only in virus entry but also virus replication such as
envelope (E) and capsid (C). Protein E and C, two major structural
proteins of flavivirus, play important roles in host cell viral interactions
and virus morphogenesis (Samsa et al., 2009; Zhang et al., 2017). Our
data suggests that pranlukast binding to E protein, may diminish virus
attachment to the cell surface leading to reduced DENV and ZIKV in-
fection in human cells. Surprisingly, pranlukast binds to NS1, a secreted
viral protein important for immune evasion and pathogenesis (Beatty
Fig. 5. Pranlukast reduces DENV and ZIKV infec-
tion of human monocytic cells and production of
virus infectious particles. A. Representative cell
counter plots for DENV and ZIKV infection of un-
treated, DMSO-treated and pranlukast-treated
(50 μM) U937 DC-SIGN-expressing cells measured by
flow cytometry using NS3 expression (gate NS3+) as
an active flavivirus replication marker. B. Inhibitory
effect of pranlukast (50–0.390 μM) on DENV and
ZIKV infection of U937-DC-SIGN cells at 24 h post-
treatment. Non-infected cells and cells infected in the
presence of DMSO (vehicle) were used as baseline for
relative infection. Data represent mean ± standard
error of the mean (SEM) of five individual experi-
ments run in duplicate. C. Vero focus forming assay
to detect virus infectious particles in supernatants
collected from U937-DC-SING infected with DENV
and ZIKV in the presence and absence of pranlukast
(50–0.390 μM). Data represent mean ± SEM of two
different experiments run in duplicate. D. Effect of
pranlukast and nilotinib on DENV and ZIKV infection
of human monocytic cells at different MOIs. U937-
DC-SIGN cells were infected with a pre-mixed of
DENV or ZIKV (MOIs: 0.1., 0.5., 1) plus pranlukast
(50, 25, 12.5 μM). Infection was evaluated after 24 h
post-treatment using flow cytometry assay. No dif-
ferences were detected between non-infected and
Mock-infected cells as well as non-treated cells and
DMSO-treated (drug vehicle control) cells infected
with either DENV or ZIKV. Data represent
mean ± SEM of five different experiments run in
duplicate.
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Fig. 6. Effect of pranlukast on DENV and ZIKV infection of human hepatocytes (Huh-7). (A) Representative images of Huh-7 cells infected with DENV (top
panel) or ZIKV (lower panel) in the presence or absence of pranlukast and nilotinib after 24 h post-treatment. Nuclei stained with Hoechst (blue). Viral protein NS3
(green). B, C. Number of infected cells per standard area (μM2) counted using ImageJ software analyses. (n = 4).
Fig. 7. Pranlukast reduces virus entry by blocking
virus attachment to the surface of human monocytic
cells. A-B. Pranlukast (50–6.25 μM) was added either si-
multaneously (pre-mixed virus plus drug) or after 2 h
post-infection. DENV and ZIKV infection was examined
after 24 h-post-treatment by flow cytometry analyses
detecting the viral protein NS3. C. DENV attachment to
cell surface was examined in the presence and absence of
pranlukast (50–6.25 μM) and nilotinib (25–3.125 μM)
with glycine acid (GlycAc) which removed any surface-
bound, non-internalized virion from the outer cell mem-
brane used as control.The amount of surface-bound virus
was measured by flow cytometry using direct virus
staining with an anti-envelope mAb (4G2-Alexa 568).
DENV relative binding for all experimental conditions
was estimated using the fluorescence signal obtained from
human monocytic cells exposed to virus alone treated
with DMSO and no virus treated cells used as background
controls.
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et al., 2015; Glasner et al., 2018; Puerta-Guardo et al., 2019b). Further
analyses using different molecular tools to evaluate its effect on virus
internalization as well as viral RNA replication and also potential
blocking effect on NS1 mediated-endothelial hyperpermeability would
help to elucidate which steps of the viral replication cycle and viral
pathogenesis are affected by pranlukast. Additionally, future studies to
examine the antiviral effect of these compounds on the infection of
other arboviruses such as chikungunya (CHIKV) should be addressed.
Importantly, these results support our findings from the virtual
screening that identified that pranlukast has a high affinity for the
envelope proteins of DENV, ZIKV, and CHIKV.
A considerable number of antineoplastic agents, commonly used for
cancer treatment, such as nilotinib (Schneider et al., 2015), displayed in
silico interaction with DENV, ZIKV and CHIKV proteins (≤−9.0 kcal/
mol). The use of this kind of molecules as antivirals is not recommended
due to their significant side effects (Afzal et al., 2015; Henβ et al., 2016;
Stein et al., 1989). In this study, nilotinib showed no antiviral activity
on DENV or ZIKV infection of human monocytes or hepatocytes in vitro
neither bind to any of the viral proteins tested, however, it appeared to
inhibit some virus attachment to the cell surface. Nilotinib has shown
antiviral activity against cytomegalovirus infection and other related
molecules such as sunitinib or erlotinib had inhibited dengue virus
Fig. 8. Pranlukast interacts with DENV proteins. A, C, E. Intrinsic fluorescence values (expressed as fluorescence arbitrary units) of three purified DENV re-
combinant proteins: NS1, capsid and envelope (200 ng/mL) alone or in combination with DMSO (0.5%), pranlukast (50 μM) or nilotinib (25 μM) were scanned at
295 nm (excitation wavelength) and four different emission wavelengths (300, 320, 340, and 360 nm). B, D, F. Protein reads collected at one emission wavelength
(300 nm). Data represent mean ± SEM of four different experiments including four replicates per run (total reads = 16). Statistical differences (Ordinary one-way
ANOVA; Mann-Whitney non-parametric test) were considered significant as p values < 0.5.
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which suggest that kinase inhibitors still represent interesting drugs
with potential antiviral activity (Bekerman et al., 2017; Pu et al., 2018;
Wolf et al., 2012).
In addition, other widely used drugs, such as the analgesic antra-
fenine (de Gara et al., 1982), the antifungals itraconazole, natamycin
and ketoconazole (Carrilo-Muñoz et al., 1996; Zuckerman and Tunkel,
1994), the antibiotics novobiocin, cefoperazone, rolitetracycline, cef-
piramide, piperacillin, dalfopristin and viomycin (Chant and Rybak,
1995; Finlay et al., 1951; Freel Meyers et al., 2003; Iakovlev and
Kaplar-Vuchevats, 1994; Mazzola et al., 1980; Nolting et al., 1996;
Pfaller et al., 2017), the antifungal natamycin (Balaguer et al., 2014),
the antimycobacterial clofazimine (Cholo et al., 2017), the vasocon-
strictor ergotamine (Tfelt-Hansen and Koehler, 2008), and the vaso-
pressin antagonist conivaptan (Annane et al., 2009), among others,
showed good affinity values with tested viral proteins. These proteins
have shown to be critical for viral-cell membrane fusion (Allison et al.,
2001; Chen et al., 1996; Crill and Roehrig, 2001; Garoff et al., 2004;
Kielian et al., 2010; Modis et al., 2004; Voss et al., 2010; Weber et al.,
2017), virus entry and recruiting of the viral genome during viral en-
capsulation and nucleocapsid creation (Ma et al., 2004; E. R. A. Oliveira
et al., 2017; Rodenhuis-Zybert et al., 2010; Marcelo M Samsa et al.,
2009), viral genome replication (Erbel et al., 2006; Lim et al., 2016; A.
F. C. da S. Oliveira et al., 2017; Patil et al., 2010; Yap et al., 2007), and
neutralization of cellular antiviral responses (Ahola and Merits, 2016;
Akhrymuk et al., 2012; Fros et al., 2015, 2010). The analgesic antra-
fenine is also one of the most promising candidates due to its strong
interaction with DENV2 E, DENV NS2B/NS3 and DENV3 NS5 proteins,
along with all CHIKV and ZIKV studied proteins. Here, itraconazole did
not inhibit the infection of DENV and ZIKV in human monocytic cells.
Interestingly, conivaptan and novobiocin showed some antiviral ac-
tivity against DENV and ZIKV at high concentrations. Novobiocin, a
natural antibiotic that inhibits DNA gyrase, has been shown to poses
some antiviral activity inhibiting vaccinia and herpesvirus (González-
Molleda et al., 2012; Sekiguchi and Shuman, 1997). This finding points
out these two compounds as potential candidates for future develop-
ment of new antiviral molecules based on their chemical structures.
Therefore, these drugs being less aggressive than anticancer agents
could be considered for future in vivo tests aimed at evaluating their
inhibitory activity against DENV, ZIKV, and CHIKV. This finding con-
stitutes an initial approach for future studies to demonstrate the po-
tential effect of these existing licensed drugs against human arboviral
infections in vitro and in vivo.
In conclusion, these findings suggest that approved drugs available
on the market may have potential therapeutic application against re-
plication/transmission of arboviruses. Further, pranlukast showed
promising antiviral activity against DENV and ZIKV primarily affecting
the viral entry step when tested on human monocytic cells and human
hepatocytes used as in vitro models for viral infection. Additionally, the
antiviral activity of pranlukast against DENV and ZIKV may be rely on
direct interaction with viral proteins critical for virus replication such
as E, NS1, and C. Further analyses using more advanced tools (e.g. ul-
trafiltration, affinity chromatograph, biolayer interferometry, surface
plasmon resonance) are needed to better characterize viral protein
binding as well as binding affinity to FDA-approved drugs or new drug
candidates. In a current scenario where no specific therapeutics and
safe vaccines for these arboviral infections are available, the re-
purposing of approved drugs targeting viral proteins required for in-
fection (Xie et al., 2015; Lim et al., 2016; de Silva et al., 2018; Glasner
et al., 2018; Puerta-Guardo et al., 2019; Subudhi et al., 2018) still re-
presents a promising approach for discovering new antiviral activities
in FDA-approved drugs that can help to fight back important human
diseases such as those caused by arboviruses.
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